Cargando…
Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
AIMS: In the randomized, placebo-controlled Colchicine Cardiovascular Outcomes Trial (COLCOT) of 4745 patients enrolled within 30 days after myocardial infarction (MI), low-dose colchicine (0.5 mg once daily) reduced the incidence of the primary composite endpoint of cardiovascular death, resuscitat...
Autores principales: | Samuel, Michelle, Tardif, Jean-Claude, Khairy, Paul, Roubille, François, Waters, David D, Grégoire, Jean C, Pinto, Fausto J, Maggioni, Aldo P, Diaz, Rafael, Berry, Colin, Koenig, Wolfgang, Ostadal, Petr, Lopez-Sendon, Jose, Gamra, Habib, Kiwan, Ghassan S, Dubé, Marie-Pierre, Provencher, Mylène, Orfanos, Andreas, Blondeau, Lucie, Kouz, Simon, L’Allier, Philippe L, Ibrahim, Reda, Bouabdallaoui, Nadia, Mitchell, Dominic, Guertin, Marie-Claude, Lelorier, Jacques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445085/ https://www.ncbi.nlm.nih.gov/pubmed/32407460 http://dx.doi.org/10.1093/ehjqcco/qcaa045 |
Ejemplares similares
-
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
por: Bouabdallaoui, Nadia, et al.
Publicado: (2020) -
Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT
por: Dubé, Marie-Pierre, et al.
Publicado: (2021) -
Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19
por: Tardif, Jean-Claude, et al.
Publicado: (2022) -
Colchicine reduces atherosclerotic plaque vulnerability in rabbits
por: Roubille, François, et al.
Publicado: (2021) -
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
por: Tardif, Jean-Claude, et al.
Publicado: (2021)